Mileage matters: long-distance performance of CARs in multiple myeloma

<p>Targeting B-cell maturation antigen with chimeric antigen receptor (CAR) T-cells is a new standard of care in relapsed/refractory multiple myeloma (RRMM). However, long-term data have currently remained sparse. In a recent study published in the <i>Journal for ImmunoTherapy of Cancer</i> by Jin <i>et al</i>, authors reported on a large cohort of 141 patients with a median follow-up of 20.2 months.…